Day: November 10, 2021

MINNEAPOLIS, Nov. 10, 2021 (GLOBE NEWSWIRE) — Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, today provided a business update and reported financial results for the quarter ended September 30, 2021. Management is hosting an earnings call today at 4:30 p.m. ET. The third quarter 2021 was marked by further meaningful clinical progress. Recent Highlights16 patients are in survival follow up since enrollment completed in December 2020, with 2 patients from cohort 2 now exceeding 26.9 and 28.7 months. Median overall survival for cohort 4 plus phase 1b (N=29) has not yet been reached. Issue Notification for patent US 11,098,005 titled “METHODS FOR PRODUCING (6S,15S)-3,8,13,18- TETRAAZAICOSANE-6,15-DIOL”. A novel process...

READING, Pa., Nov. 10, 2021 (GLOBE NEWSWIRE) — EnerSys (NYSE: ENS), the global leader in stored energy solutions for industrial applications, announced today results for its second quarter of fiscal 2022, which ended on October 3, 2021.Second Quarter FY 22 HighlightsNet sales of $791M up 12% vs. Q2’21 Record backlog now over $1.0B Aggressively driving price to catch inflation Supply chain slowed Q2 shipments, impacting earningsBank debt leverage at 2.0X Hagen closure substantially complete TPPL demand strong; output nearing $1.2B p.a. New product initiatives gaining market acceptanceKey Results from Operations by Segments ($ in millions)    Q2 FY22   Q2 FY21   % ChangeEnergy Systems            Net Sales   $ 369.8    $ 340.8    8.5    %Operating Earnings   1.2   22.8   (95.1 )  Adjusted...

IZEA Q3 2021 Bookings Conversion ChartA comparison of Managed Services Bookings to Revenue Conversion by quarter from 2019-2021.ORLANDO, Fla., Nov. 10, 2021 (GLOBE NEWSWIRE) — IZEA Worldwide, Inc. (NASDAQ: IZEA), the premier provider of influencer marketing technology, data, and services for the world’s leading brands, reported its financial and operational results for the third quarter ended September 30, 2021. Q3 2021 Financial Summary Compared to Q3 2020Total revenue increased 88% to an all-time record $7.6 million, compared to $4.0 million. Managed Services unit revenue increased 104% to $7.2 million, compared to $3.5 million. SaaS Services unit revenue decreased 13% to $454,000, compared to $522,000. Total costs and expenses increased 72% to $9.1 million, compared to $5.3 million. Net loss was $1.5 million,...

– 34.3% Year-over-Year Growth in Third Quarter 2021 Gross Written Premiums to $177.6 Million – – 86.5% Year-over-Year Growth in Third Quarter Net Earned Premium to $52.0 Million – – Net Income of $6.5 Million, Diluted Earnings per Share of $0.13 – – Adjusted Net Income of $7.7 Million, Adjusted Diluted Earnings per Share of $0.15 – WAYZATA, Minn., Nov. 10, 2021 (GLOBE NEWSWIRE) — Trean Insurance Group, Inc. (Nasdaq: TIG) (“Trean” or the “Company”), a leading provider of products and services to the specialty insurance market, today reported results for the third quarter ended September 30, 2021. “We had a very solid third quarter,” said Andrew M. O’Brien, Chief Executive Officer of Trean. “We generated an 88.3% combined ratio for the third quarter compared to a 91.8% combined ratio...

Closed initial public offering raising net proceeds after expenses of $32.3 million. Added two new independent Directors and increased diversity across our Board of Directors. Completed patient dosing of the first cohort of a Phase 1 clinical trial of INB-100 in leukemia patients undergoing hemopoietic stem cell transplant. Announced peer-reviewed publication of preclinical data for INB-200 in Scientific Reports, a Nature Portfolio journal.NEW YORK, Nov. 10, 2021 (GLOBE NEWSWIRE) — IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell therapies utilizing its DeltEx platform, today announced financial results and operational highlights for the third quarter ended September 30, 2021. In addition, the Company provided an overview of recent...

— Company Expects to Submit VAX-24 IND Application to FDA in Q1 2022 — — Completed Manufacture of VAX-24 GMP Drug Product and GLP Toxicology Study — FOSTER CITY, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) — Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, today announced financial results for the third quarter ended September 30, 2021 and provided a business update. “We continue to make meaningful progress with the IND-enabling activities for VAX-24, our lead, 24-valent pneumococcal conjugate vaccine (PCV) candidate, having completed both the manufacture of the GMP drug product and the GLP toxicology study,” said Grant Pickering,...

Q3 Gross Merchandise Value Increased 25% Year-Over-Year to $109 millionQ3 Net Revenue Increased 22% Year-Over-Year to $25.6 million NEW YORK, Nov. 10, 2021 (GLOBE NEWSWIRE) — 1stdibs.com, Inc. (NASDAQ: DIBS), a leading online marketplace for luxury design products, today reported financial results for its third quarter ended September 30, 2021. Third Quarter 2021 Financial HighlightsNet revenue was $25.6 million, an increase of 22% year-over-year. Gross profit was $18.1 million, an increase of 23% year-over-year. Gross margin was 70.6%, compared to 69.9% in the third quarter 2020. GAAP net loss was $6.6 million, compared to $1.4 million in the third quarter 2020. Non-GAAP Adjusted EBITDA and Adjusted EBITDA Margin was $(5.4) million and (21.0)%, respectively, compared to $(0.5) million and (2.2)%, respectively, in the third quarter...

VOR33 on track with initial clinical data expected in the first half of 2022 Announced pipeline expansion with first multi-targeted Treatment System simultaneously targeting CD33 and CLL-1 for AMLCAMBRIDGE, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) — Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period ended September 30, 2021, and provided a business update.  “Our main focus during the third quarter of 2021 has been on site activation and patient recruitment in the Phase 1/2a trial of VOR33 for patients with AML. The initial data from this trial, expected in the first half of 2022, is intended to provide first-in-human demonstration of CD33 biological redundancy,” said Robert Ang, M.B.B.S., MBA, Vor’s President and Chief Executive Officer....

Solid Q3 Results Across Businesses TORONTO, Nov. 10, 2021 (GLOBE NEWSWIRE) — ECN Capital Corp. (TSX: ECN) (“ECN Capital” or the “Company”) today reported financial results for the three-month period ended September 30, 2021. Service Finance has been re-classified as a discontinued operation and is not included in operating results. For the three-month period ended September 30, 2021, ECN Capital reported Adjusted net income applicable to common shareholders from continuing operations of $13.7 million or $0.06 per share (basic) versus $11.1 million or $0.05 per share (basic) for the previous three-month period and $7.9 million or $0.03 per share (basic) for the same period last year. “ECN reported excellent results in Q3”, said Steven Hudson, CEO of ECN Capital Corp. “$0.06 per share, excluding Service Finance, which is classified...

FREMONT, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) — Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced financial results for the third quarter ended September 30, 2021, as well as business highlights. “This quarter we made significant progress towards the resubmission of the NDA for M207 with receipt of top-line data from our pharmacokinetic study,” said Steven Lo, president and chief executive officer of Zosano. “We expect to receive written feedback from the FDA through a Type C meeting by mid-December and expect that their feedback will enable us to further refine our regulatory strategy and to provide an update on our resubmission plans for the NDA. We believe there is a significant need for new acute treatment options for migraine as it is estimated that more than 70% of migraine...